250 related articles for article (PubMed ID: 29133560)
21. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Zhang C; McIlleron H; Ren Y; van der Walt JS; Karlsson MO; Simonsson US; Denti P
Antivir Ther; 2012; 17(1):25-33. PubMed ID: 22267466
[TBL] [Abstract][Full Text] [Related]
23. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
[TBL] [Abstract][Full Text] [Related]
24. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
Seddon JA; Garcia-Prats AJ; Purchase SE; Osman M; Demers AM; Hoddinott G; Crook AM; Owen-Powell E; Thomason MJ; Turkova A; Gibb DM; Fairlie L; Martinson N; Schaaf HS; Hesseling AC
Trials; 2018 Dec; 19(1):693. PubMed ID: 30572905
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
Mase SR; Jereb JA; Gonzalez D; Martin F; Daley CL; Fred D; Loeffler AM; Menon LR; Bamrah Morris S; Brostrom R; Chorba T; Peloquin CA
Pediatr Infect Dis J; 2016 Apr; 35(4):414-21. PubMed ID: 26658531
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.
Garcia-Prats AJ; Draper HR; Thee S; Dooley KE; McIlleron HM; Seddon JA; Wiesner L; Castel S; Schaaf HS; Hesseling AC
Antimicrob Agents Chemother; 2015 Oct; 59(10):6073-9. PubMed ID: 26195507
[TBL] [Abstract][Full Text] [Related]
27. Fluoroquinolones for the treatment of tuberculosis in children.
Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
[TBL] [Abstract][Full Text] [Related]
28. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
Malik AA; Brooks MB; Siddiqui S; Fuad J; Peloquin CA; Amanullah F; Jaswal M; Becerra MC; Hussain H; Yuen CM
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803975
[TBL] [Abstract][Full Text] [Related]
30. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
Kempker RR; Barth AB; Vashakidze S; Nikolaishvili K; Sabulua I; Tukvadze N; Bablishvili N; Gogishvili S; Singh RS; Guarner J; Derendorf H; Peloquin CA; Blumberg HM
Antimicrob Agents Chemother; 2015; 59(6):3149-55. PubMed ID: 25779583
[TBL] [Abstract][Full Text] [Related]
31. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Galileya LT; Wasmann RE; Chabala C; Rabie H; Lee J; Njahira Mukui I; Hesseling A; Zar H; Aarnoutse R; Turkova A; Gibb D; Cotton MF; McIlleron H; Denti P
PLoS Med; 2023 Nov; 20(11):e1004303. PubMed ID: 37988391
[TBL] [Abstract][Full Text] [Related]
32. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
[TBL] [Abstract][Full Text] [Related]
33. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.
Wasserman S; Denti P; Brust JCM; Abdelwahab M; Hlungulu S; Wiesner L; Norman J; Sirgel FA; Warren RM; Esmail A; Dheda K; Gandhi NR; Meintjes G; Maartens G
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617089
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
Ghimire S; Maharjan B; Jongedijk EM; Kosterink JGW; Ghimire GR; Touw DJ; van der Werf TS; Shrestha B; Alffenaar JC
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782999
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
[TBL] [Abstract][Full Text] [Related]
36. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
[TBL] [Abstract][Full Text] [Related]
37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
38. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
Purchase SE; Garcia-Prats AJ; De Koker P; Draper HR; Osman M; Seddon JA; Schaaf HS; Hesseling AC
Pediatr Infect Dis J; 2019 Jun; 38(6):608-610. PubMed ID: 30550511
[TBL] [Abstract][Full Text] [Related]
39. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
[TBL] [Abstract][Full Text] [Related]
40. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
